Large cell neuroendocrine carcinoma of the lung: What we have to do  by Filosso, Pier Luigi
References
1. Suzuki K, Murtaza B, Heslop L, Morgan
JE, Smolenski RT, Suzuki N, et al. Single
fibers of skeletal muscle as a novel graft for
cell transplantation to the heart. J Thorac
Cardiovasc Surg. 2002;123:984-92.
2. Menasche´ P, Hagege AA, Scorcin M,
Pouzet B, Desnos M, Duboc D, et al. Myo-
blast transplantation for heart failure. Lan-
cet. 2001;357:279-80.
3. Pouzet B, Vilquin JT, Hagege A, Scorcin
M, Messas E, Fiszman M, et al. Factors
effecting functional outcome of autologous
skeletal myoblast transplantation. Ann Tho-
rac Surg. 2001;71:844-51.
4. Neumeyer AM, DiGregorio DM, Brown
RH Jr. Arterial delivery of myoblasts to
skeletal muscle. Neurology. 1992;42:2258-
62.
5. Suzuki K, Murtaza B, Suzuki N, Smolenski
RT, Yacoub MH. Intracoronary in fusion of
skeletal myoblasts improves cardiac func-
tion in doxorubicin-induced heart failure.
Circulation. 2001;104 Suppl 1:I213-7.
doi:10.1067/mtc.2003.288
Reply to the Editor:
We appreciate the interest of Sim and col-
leagues in our article describing the im-
plantation of single, isolated skeletal mus-
cle fibers into the heart. We agree that
many important questions need to be an-
swered before further clinical trials of myo-
blast transplantation into the heart.
A major issue is the mechanism by
which skeletal myoblast transplantation
can improve cardiac function. Sim and
colleagues’ suggestion that the improve-
ment in myocardial function is directly
related to the number of myoblasts im-
planted has not been firmly established.
We consider the quality of cells im-
planted to be as important as, or perhaps
even more important than, cell number.1
In addition, only one recent study with
donor cardiac myocytes has attempted to
adequately quantify graft cell survival
with quantitative real-time polymerase
chain reaction, and no direct correlation
between numbers of surviving donor-de-
rived cells and functional improvement
was made in that study.2
It should be noted that the issues re-
garding the adverse effects of prolonged
in vitro culture on skeletal myoblasts are
far from theoretical, as suggested by Sim
and colleagues. There is clear evidence
for the susceptibility to infection, as well
as altered immunogenicity and adverse
effects on myogenicity.3 With respect to
the risk of coronary embolism after cell
transplantation, we have reported that in-
fusion of more than 2 million myoblasts
in a volume of 1mL into the coronary
circulation of the rat heart results in em-
bolization, with edema and cardiac ar-
rest.4
Sim and colleagues suggest that the
functional benefit of myoblast transplanta-
tion is due, at least in an ischemic heart
failure model, to the formation of new mus-
cle (“neomyogenesis”) with “phenotypic
features similar to skeletal and cardiac
muscle.” This statement is not clear, and
such a mechanism would require extensive
functional, electrophysiological, and mo-
lecular characterization.
The relevance of the discordant hu-
man-to-pig xenogenic model cited by
Sim and colleagues is not clear, and it is
unlikely that a significant degree of myo-
blast survival would be seen after graft-
ing with only transient immunosuppres-
sion—although the protocol for this is
not detailed. We find interpretation of the
staining in the figure difficult. With re-
spect to labeling, the promoter driving
reporter lacZ expression is not stated;
thus one cannot be absolutely certain as
to the identity of the stained cells in the
presented figure. The varied distribution
of the X-gal stain is difficult to explain,
and counterstaining with skeletal myo-
sin–specific antibody, as reported in our
own data, would be informative; an ad-
ditional nuclear marker would confirm
the specificity of the stain.
The key findings in our study are that
myogenic precursor cells derived from the
parent fibers appeared to survive, prolifer-
ate, and differentiate within the cardiac mi-
croenvironment. Further, this treatment im-
proved cardiac function in ischemic and
dilated cardiomyopathy models to a degree
that was far beyond what one might expect
for the amount of new muscle formed. We
have proposed at least two possible causes
for this remarkable effect. One is a para-
crine effect resulting in neoangiogenesis,
as shown in our article; the other is the
endogenous protection afforded to the res-
ident satellite cells by the parent fiber. This
latter effect may be important in enhancing
graft cell survival in the most hazardous
acute phase after grafting and may also
deliver satellite cells that have some impor-
tant qualitative differences. We consider
the skeletal muscle fiber system to be
promising, although further studies are
needed to investigate the effects that we
have proposed.
Bari Murtuza
Ken Suzuki
Magdi H. Yacoub
Harefield Hospital Heart Science Centre
Imperial College Faculty of Medicine
London, United Kingdom
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Large cell neuroendocrine
carcinoma of the lung: What we
have to do
To the Editor:
I read with interest the excellent article of
Takei and colleagues1 about large cell neu-
roendocrine carcinoma (LCNC) of the
lung. This series represents the largest ever
published in English language literature.
The family of neuroendocrine tumors of
the lung has recently been the object of
study by several pathologists and surgeons.
The recent World Health Organization
classification criteria2 consider neuroendo-
crine tumors of the lung as a distinct subset
of neoplasm with specific morphologic, ul-
trastructural, immunohistochemical, and
molecular characteristics. Travis and asso-
ciates3 distinguish between typical and
atypical carcinoid, LCNC, and small cell
neuroendocrine carcinoma of the lung. Of
these tumors, LCNCs appear to have an
intermediate biologic behavior between
atypical carcinoid and small cell carcino-
ma.3 LCNCs have a tendency to spread
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early, yielding mediastinal lymph node me-
tastases or distant metastases (generally in
the liver or in the brain) at the time of
diagnosis.
Correct preoperative diagnosis of neu-
roendocrine carcinoma of the lung (and
also of LCNC) is really difficult to obtain
either by bronchoscopy or by transthoracic
biopsy; in the case of clinical N2 neuroen-
docrine carcinoma, a surgical approach can
be considered, because these tumors do not
respond to neoadjuvant therapy.4 This
could be appropriate in case of bronchial
carcinoid, but not in case of LCNC. For
these tumors, I believe, neoadjuvant treat-
ment is mandatory because of their aggres-
sive biologic behavior.
In this study Takei and colleagues1
pointed out the importance of the immuno-
histochemical assessment, with the detec-
tion of chromogranin A staining in neo-
plastic cells. We must remember that
LCNCs, because they are neuroendocrine
carcinomas, express somatostatin recep-
tors, which can be easily detected in vitro
by reverse transcriptase polymerase chain
reaction.5 In vivo expression of these re-
ceptors is provided by indium 111–tagged
diethylenetriaminepentaacetic acid pente-
treotide (OctreoScan, OCT) scintigra-
phy.6,7 This procedure is widely accepted
both in the preoperative evaluation of neu-
roendocrine carcinoma, because of its ef-
fectiveness in detecting mediastinal or dis-
tant metastases with high sensitivity, and in
follow-up for early detection of tumor re-
currences or distant metastases.8 In case of
positive OCT scintigraphy result, therapy
with octreotide (new generation somatosta-
tin analog) might be considered, alone or in
association with chemotherapy. I believe
that such an important biologic concept
might be considered in the correct multi-
disciplinary treatment of LCNC of the
lung. Octreotide has been proved to be
effective in controlling metastatic growth,
well tolerated by the patient, and without
important side effects.8,9
In conclusion, I congratulate Takei and
colleagues1 for this excellent article on
such a difficult matter. I recommend the
use of OCT scintigraphy in the preopera-
tive evaluation of these patients and in their
follow-up. Furthermore the use of oct-
reotide (in the case of positive results of
OCT scintigraphy), in association with tra-
ditional adjuvant therapy, might be consid-
ered to reduce the risk of tumor recurrence
or distant metastases.
Pier Luigi Filosso, MD
University of Torino Italy
San Giovanni Battista Hospital
Department of Thoracic Surgery
Via Genova, 3
10126 Torino, Italy
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Reply to the Editor:
We appreciate the thoughtful comments by
Filosso on our recent article1 describing the
clinicopathologic aspects of large cell neu-
roendocrine carcinoma (LCNC) of the
lung.
The histologic type of LCNC of the
lung has been included as the subtype of
large cell carcinoma in the revised World
Health Organization classification of lung
and pleural tumors in 1999.2 The clinico-
pathologic features, however, have not
been described in detail. Especially little is
known about the response of LCNC to the
chemotherapy and radiotherapy. Consider-
ing the analogy of LCNC to the small cell
histologic type, a multimodal therapeutic
approach might be expected to be promis-
ing.
As Filosso pointed out, we also have a
great interest in the expression of soma-
tostatin receptors in LCNC. If these recep-
tors are expressed frequently in LCNC, oc-
treotide scintigraphy with somatostatin
analog (OctreoScan) would reasonably be
of great utility in the preoperative evalua-
tion of extent of disease of LCNC. Indeed,
carcinoid tumor and small cell carcinoma
have already been shown to be well ana-
lyzed by octreotide scintigraphy.3,4 As for
LCNC, however, according to a report by
Jiang and colleagues,5 only 9 (40.9%) of 22
cases were shown to stain positively for
somatostatin, and these tumor cells do not
necessarily express somatostatin receptors.
Whether octreotide scintigraphy can be
used depends on the rate of expression of
somatostatin receptors. At present no data
are available on the expression of soma-
tostatin receptors in LCNC.
Furthermore, the preoperative establish-
ment of a histologic diagnosis of LCNC is
crucial in planning the LCNC-specific
treatment strategy. However, it is actually
quite difficult to get the histologic or cyto-
logic diagnosis of LCNC simply by the
evaluation of tiny preoperative biopsy
specimen. Novel LCNC-specific markers
(“immunohistochemically detectable”)
must be sought; such markers would easily
enable the histologic diagnosis of LCNC.
Again, we pointed out that LCNC
should be recognized as one of the poorest
prognostic subgroups in lung cancer, and
novel therapeutic approaches should be es-
tablished. Further accumulation of clinico-
pathologic characteristics, especially the
response to nonsurgical treatment, is the
most important issue. The histologic clas-
sification of lung tumors with neuroendo-
crine phenotype also seems to need further
revision in the near future.
Hidefumi Takei, MD
Hisao Asamura, MD
Yoshihiro Matsuno, MD
National Cancer Center Hospital
Tokyo, Japan
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